FDA’s new guidance on AI in drug development centers the risk introduced by the technology

Taking stock of the drug industry, from the lab to the medicine chest

January 6, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FDA's new guidance on AI in drug development centers the risk introduced by the technology After nearly a decade of machine learning innovations, the FDA has issued its first draft guidance on the use of AI in drug development. By Katie Palmer STAT+ | The biotech scorecard for the first quarter: 16 stock-moving events to watch Stock-moving biotech events for the fourth quarter include clinical trial readouts from Ultragenyx, Akero Therapeutics, and Incyte. By Adam Feuerstein Eli Lilly seeks to join lawsuit on compounded drugs Today's biotech news includes a biotech scorecard for Q1, National Medal of Technology and Innovation winners, and more. By Meghana Keshavan Mike Reddy for STAT What Covid tried to teach us — and why it will matter in the next pandemic Five years after the start of the outbreak, here are some issues we will likely have to deal with when the next pandemic hits. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser